Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-In-Human, Dose-Escalation Clinical Study to Evaluate the Safety and Tolerability of Single and Multiple-Ascending Intravenous and Subcutaneous Doses of OSE-127 in Healthy Volunteers

Trial Profile

A Phase 1, First-In-Human, Dose-Escalation Clinical Study to Evaluate the Safety and Tolerability of Single and Multiple-Ascending Intravenous and Subcutaneous Doses of OSE-127 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2018

At a glance

  • Drugs OSE 127 (Primary) ; OSE 127 (Primary)
  • Indications Autoimmune disorders; Sjogren's syndrome; Ulcerative colitis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Dec 2018 Status changed from planning to recruiting, as reported in an OSE Immunotherapeutics media release.
    • 20 Dec 2018 According to an OSE Immunotherapeutics media release, the first healthy volunteers have been dosed in the trial.
    • 26 Nov 2018 According to an OSE Immunotherapeutics media release, the company has received authorization by Federal Agency for Medicines and Health Products (FAMH) and Belgian Ethics Committee to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top